DOJ Manual Updated To Enhance Focus On Targeting Individual Execs
This article was originally published in The Gray Sheet
The updated US Attorney’s Manual instructs government lawyers to focus on individuals from the launch of civil or criminal investigations into a company, and not to consider individual’s ability to pay a judgment in deciding whether to pursue charges.
You may also be interested in...
The US Department of Justice recently announced the largest-ever civil settlement in a device-related False Claims Act case. But otherwise it was a textbook FCA case, attorneys say, and many device companies still have a lot of work to do to ensure compliance and that their executives stay out of trouble. This is the first article in an occasional series in which Medtech Insight talks to attorneys to get the best takes on hot legal topics.
Two former executives from J&J's Acclarent division were found not guilty of felony charges but convicted on misdemeanor counts. Prior to being acquired by J&J, Acclarent allegedly marketed its Relieva Stratus sinus dilation device as a steroid-delivery system, even though the FDA had cleared the device only to deliver saline.
A store clerk accused of selling misbranded synthetic drugs was sentenced on misdemeanor violations of the Act. An appeals court verdict upholding the conviction could give FDA more latitude to pursue individuals responsible for violations in the drug and device space, attorneys say.